Insys Therapeutics Inc., of Phoenix, said preliminary results of a preclinical pharmacokinetics study of its investigational epinephrine nasal spray appeared to achieve bioavailability similar to that of intramuscular injection with Epipen 0.3 mg (epinephrine, Mylan NV). The study also demonstrated rapid drug absorption with the epinephrine nasal spray, the company said.